FLURESS- fluorescein sodium and benoxinate hydrochloride solution/ drops
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Fluress® (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP) is a sterile ophthalmic solution combining a disclosing agent with an anesthetic agent.
Fluorescein sodium is a disclosing agent with molecular formula C20H10Na2O5, molecular weight 376.28, and chemical structure:
Spiro[isobenzofuran-1 (3H), 9'-[9H]xanthene]-3-one. 3'6'-dihydroxy, Disodium salt
Benoxinate Hydrochloride is an anesthetic agent with molecular formula C17H28N2O3•HCl, molecular weight 344.88, and chemical structure:
Benzoic acid, 4-amino-3-butoxyl-,2-(diethylamino) ethyl ester, monohydrochloride
Each mL contains:
Actives: Benoxinate Hydrochloride 4 mg (0.4%). Fluorescein Sodium 2.5 mg (0.25%).
Preservative: Chlorobutanol 10 mg (1%).
Inactives: Boric Acid, Povidone, Sodium Hydroxide and/or Hydrochloric Acid may be added to adjust pH (4.3 to 5.3), and Purified Water USP.
Fluress® is the combination of a disclosing agent with a rapidly acting anesthetic agent of short duration.
For procedures requiring a disclosing agent in combination with an anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures.
NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY.
Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.
KEEP OUT OF REACH OF CHILDREN.
Fluress® (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP) should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.
Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.
Occasional temporary stinging, burning and conjunctival redness have been reported after use of ocular anesthetics, as well as a rare severe, immediate-type, apparently hyperallergic corneal reaction with acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing or large areas of necrotic epithelium, corneal filaments and sometimes, iritis with descemetitis.
Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.
Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.
Deep ophthalmic anesthesia: 2 drops in each eye at 90 second intervals for 3 instillations.
NOTE: The use of an eye patch is recommended.
Fluress® is supplied as 5 mL contained in a 10 mL plastic dropper bottle with a separate sterile dropper applicator. (NDC 17478-640-10)
Refrigerate at 2° to 8°C (36° to 46°F). User may store at room temperature for up to one month. Store in carton until empty to protect from light. Keep tightly closed.
U.S. PATENT NO. 3306820
CANADIAN PATENT NO. 835940
Manufactured by: Akorn, Inc.
Lake Forest, IL 60045
FS00N Rev 05/08
NDC 17478-640-10 Akorn Logo
Fluorescein Sodium and
Ophthalmic Solution, USP
(0.25% / 0.4%)
Rx only Sterile
fluorescein sodium and benoxinate hydrochloride solution/ drops
|Labeler - Akorn, Inc. (062649876)|
|Akorn, Inc.||155135783||MANUFACTURE, REPACK, ANALYSIS, LABEL, PACK, RELABEL, STERILIZE|